The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond

A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab

(2018) Y Satoh et al.   LUPUS

The Initiation, but Not the Persistence, of Experimental Spondyloarthritis Is Dependent on Interleukin-23 Signaling

(2018) Melissa N. van Tok et al.   Frontiers in Immunology

Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease

(2018) Sayam Dubash et al.   RHEUMATOLOGY

Learning from the youngsters: ixekizumab in active ankylosing spondylitis

(2018) Xenofon Baraliakos et al.   LANCET

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

(2018) Désirée van der Heijde et al.   LANCET

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo Controlled Trial in Patients with Prior Inadequate Response or Intolerance to Tumor Necrosis Factor

(2018) Atul Deodhar et al.   Arthritis & Rheumatology

Secukinumab-induzierter subakut-kutaner Lupus erythematodes

(2017) C. Wehrmann et al.   HAUTARZT

IL-23/Th17 targeted therapies in SAPHO syndrome. A case series

(2017) Daniel Wendling et al.   JOINT BONE SPINE

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)

(2017) Désirée van der Heijde et al.   JOURNAL OF RHEUMATOLOGY

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

(2017) Peter Nash et al.   LANCET

Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study

(2017) H. Marzo-Ortega et al.   ARTHRITIS CARE & RESEARCH

In vitro-engineered non-antibody protein therapeutics

(2017) Rudo Simeon et al.   Protein & Cell

The Paradox of Bone Formation and Bone Loss in Ankylosing Spondylitis: Evolving New Concepts of Bone Formation and Future Trends in Management

(2017) Marina N. Magrey et al.   Current Rheumatology Reports

Secukinumab-Induced Psoriasiform Eruption

(2017) Michael J. Sladden et al.   JAMA Dermatology

Secukinumab for Acrodermatitis Continua of Hallopeau

(2017) David Muggli et al.   JAMA Dermatology

Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study

(2017) Francisco J. Blanco et al.   Arthritis & Rheumatology

Brief Report: Group 3 Innate Lymphoid Cells in Human Enthesis

(2017) Richard J. Cuthbert et al.   Arthritis & Rheumatology

New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice

(2017) Sayam Dubash et al.   Therapeutic Advances in Chronic Disease

Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study

(2016) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study

(2016) Jürgen Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

(2016) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

A revolutionary therapeutic approach for psoriasis: bispecific biological agents

(2016) T. Torres et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Adalimumab in Patients with Active Noninfectious Uveitis

(2016) Glenn J. Jaffe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Single Nucleotide Polymorphism in the Il17ra Promoter Is Associated with Functional Severity of Ankylosing Spondylitis

(2016) Jose Ramón Vidal-Castiñeira et al.   PLoS One

Chronic skin inflammation leads to bone loss by IL-17–mediated inhibition of Wnt signaling in osteoblasts

(2016) Özge Uluçkan et al.   Science Translational Medicine

IL-17-producing γδ T cells enhance bone regeneration

(2016) Takehito Ono et al.   Nature Communications

Interleukin-23-Dependent γ/δ T Cells Produce Interleukin-17 and Accumulate in the Enthesis, Aortic Valve, and Ciliary Body in Mice

(2016) Annika Reinhardt et al.   Arthritis & Rheumatology

Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis

(2015) Francesco Ciccia et al.   ANNALS OF THE RHEUMATIC DISEASES

The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment

(2015) H. Jethwa et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Camelid nanobodies: killing two birds with one stone

(2015) Aline Desmyter et al.   CURRENT OPINION IN STRUCTURAL BIOLOGY

T cell subsets and their signature cytokines in autoimmune and inflammatory diseases

(2015) Itay Raphael et al.   CYTOKINE

Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability

(2015) Jacob S. Lee et al.   IMMUNITY

Gut-Busters: IL-17 Ain’t Afraid of No IL-23

(2015) Natasha Whibley et al.   IMMUNITY

Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions

(2015) Dhavalkumar D. Patel et al.   IMMUNITY

Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis

(2015) Yun Ling et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

(2015) Christopher E M Griffiths et al.   LANCET

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Iain B McInnes et al.   LANCET

'MHC-I-opathy'—unified concept for spondyloarthritis and Behçet disease

(2015) Dennis McGonagle et al.   Nature Reviews Rheumatology

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

(2015) Mark Lebwohl et al.   NEW ENGLAND JOURNAL OF MEDICINE

American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

(2015) Michael M. Ward et al.   Arthritis & Rheumatology

Spinal Radiographic Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Blocking Therapy: A Prospective Longitudinal Observational Cohort Study

(2015) Fiona Maas et al.   PLoS One

Inflammation, new bone formation and treatment options in axial spondyloarthritis

(2014) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-17 Induces an Atypical M2-Like Macrophage Subpopulation That Regulates Intestinal Inflammation

(2014) Kenichiro Nishikawa et al.   PLoS One

Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography

(2013) X Baraliakos et al.   ANNALS OF THE RHEUMATIC DISEASES

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial

(2013) Jürgen Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis

(2013) Xenofon Baraliakos et al.   ANNALS OF THE RHEUMATIC DISEASES

In Situ Analysis of Interleukin-23- and Interleukin-12-Positive Cells in the Spine of Patients With Ankylosing Spondylitis

(2013) Heiner Appel et al.   ARTHRITIS AND RHEUMATISM

Combinatorial Control of Th17 and Th1 Cell Functions by Genetic Variations in Genes Associated With the Interleukin-23 Signaling Pathway in Spondyloarthritis

(2013) Maryaline Coffre et al.   ARTHRITIS AND RHEUMATISM

Pivotal Roles of T-Helper 17-Related Cytokines, IL-17, IL-22, and IL-23, in Inflammatory Diseases

(2013) Ning Qu et al.   Clinical & Developmental Immunology

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

(2013) Dominique Baeten et al.   LANCET

The critical role of interleukin-23 in spondyloarthropathy

(2013) Jonathan P. Sherlock et al.   MOLECULAR IMMUNOLOGY

Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci

(2013) Adrian Cortes et al.   NATURE GENETICS

Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials

(2013) Andrew D. Dick et al.   OPHTHALMOLOGY

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

The multi-faceted nature of HLA class I dimer molecules

(2012) Elaine C. Campbell et al.   IMMUNOLOGY

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells

(2012) Jonathan P Sherlock et al.   NATURE MEDICINE

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

(2011) J. Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility

(2011) David M Evans et al.   NATURE GENETICS

The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans

(2011) Paola Di Meglio et al.   PLoS One

HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats

(2009) Monica L. DeLay et al.   ARTHRITIS AND RHEUMATISM

Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis

(2008) Désirée van der Heijde et al.   ARTHRITIS AND RHEUMATISM